ACE and glomerular disorder: Starting from the established benefit of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) as our first-line, standard-of-care therapy for glomerular disease [7], and asking what mediates their anti-proteinuric, podocyte-specific effect, has revealed an interesting answer: a Ca2+-mediated pathway connects the angiotensin type 1 receptor (AT1R) to podocyte cytoskeletal dynamics.